|
|
|
| Research progress on the mechanism of depression and anxiety of antihyperglycemics |
| ZHOU Zijing YAN Shuang |
| Department of Endocrinology, the Fourth Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin 150001, China |
|
|
|
Abstract Depression is one of the risk factors for type 2 diabetes mellitus (T2DM), and the incidence of depression in T2DM patients is significantly higher than that in non-T2DM population. Depression is often accompanied by severe anxiety symptoms. There are few systematic studies on the relationship between T2DM and depression and anxiety state. There are overlapping biological effects in the pathogenesis and treatment mechanism of both. Existing studies have found that Metformin, Thiazolidinedione, GLP-1 receptor agonists, DPP-4 inhibitors, insulin and other antihyperglycemics may relieve depression and anxiety state through neurobiochemical, neuroendocrine, neuroimmune and other mechanisms. Therefore, it is of great clinical significance to explore the biological mechanism of antihyperglycemics in relieving depression and anxiety state.
|
|
|
|
|
|
[1] Gonzalez JS，Hood KK，Esbitt SA，et al. Psychiatric and psychosocial issues among individuals living with diabetes [M]. Diabetes in America，2017.
[2] Ogurtsova K，da Rocha Fernandes JD，Huang Y et al. IDF Diabetes Atlas：Global estimates for the prevalence of diabetes for 2015 and 2040 [J]. Diabetes Res Clin Pract，2017，128：40-50.
[3] Wang L，Gao P，Zhang M，et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013 [J]. JAMA，2017，317：2515-2523.
[4] Kessing LV，Rytgaard HC，Ekstr?覬m CT，et al. Antidiabetes Agents and Incident Depression：A Nationwide Population-Based Study [J]. Diabetes Care，2020，43（12）：3050-3060.
[5] Fan J，Li D，Chen HS，et al. Metformin produces anxiolytic-like effects in rats by facilitating GABAA receptor trafficking to membrane [J]. Br J Pharmacol，2019，176（2）：297-316.
[6] Zemdegs J，Martin H，Pintana H，et al. Metformin Promotes Anxiolytic and Antidepressant-Like Responses in Insulin-Resistant Mice by Decreasing Circulating Branched-Chain Amino Acids [J]. J Neurosci，2019，39（30）：5935-5948.
[7] Esmaeili MH，Bahari B，Salari AA. ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity，depression-and anxiety-related symptoms in a rat model of Alzheimer’s disease [J]. Brain Res Bull，2018，137：265-276.
[8] Mirza R，Sharma B. A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress [J]. Chem Biol Interact，2019，311：108758.
[9] 熊庭旺，吴芹，刘杰，等.基于神经递质途径抗焦虑中药及其复方研究进展[J].中国中药杂志，2020，45（1）：22-27.
[10] 和昱辰，张波，瞿玮，等.血清单胺类神经递质及其代谢产物在重度抑郁症及抑郁共病焦虑障碍诊断中的应用[J].第三军医大学学报，2014，36（8）：806-810.
[11] 冯国华.首发抑郁障碍、焦虑障碍、躯体形式障碍的神经内分泌机制研究及治疗前后的比较研究[D].昆明：昆明医科大学，2017.
[12] Beurel E，Toups M，Nemeroff CB. The Bidirectional Relationship of Depression and Inflammation：Double Trouble [J]. Neuron，2020，107（2）：234-256.
[13] 张翕婷，王怡，李霖，等.炎性因子与其他抑郁相关因素关系的研究现状[J].中国临床药理学杂志，2018，34（21）：2568-2571.
[14] 邓洁，李仲铭，张航铭，等.神经可塑性与认知功能关系研究进展[J].中国组织化学与细胞化学杂志，2019，28（5）：70-74.
[15] Wang YW，He SJ，Feng X，et al. Metformin：a review of its potential indications [J]. Drug Des Devel Ther，2017， 11：2421-2429.
[16] Poggini S，Golia MT，Alboni S，et al. Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus [J]. Neural Plast，2019，2019：4651031.
[17] Ji S，Wang L，Li L. Effect of Metformin on Short-Term High-Fat Diet-Induced Weight Gain and Anxiety-Like Behavior and the Gut Microbiota [J]. Front Endocrinol（Lausanne），2019，10：704.
[18] Ge XH，Zhu GJ，Geng DQ，et al. Metformin protects the brain against ischemia/reperfusion injury through PI3K/Akt1/JNK3 signaling pathways in rats [J]. Physiol Behav，2017，170：115-123.
[19] Lv W，Wang X，Xu Q，et al. Mechanisms and Characteristics of Sulfonylureas and Glinides [J]. Curr Top Med Chem，2020，20（1）：37-56.
[20] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[21] 赵承奇，尚军，邢鲁艳.糖尿病治疗药物研究进展[J].人民军医，2019，62（8）：768-773.
[22] Su WJ，Peng W，Gong H，et al. Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance [J]. J Neuroinflammation，2017，14（1）：210.
[23] 庄会艳.噻唑烷二酮类药物的药理作用研究[J].医学食疗与健康，2019（17）：88-90.
[24] Domi E，Uhrig S，Soverchia L，et al. Genetic Deletion of Neuronal PPARγ Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety：An Effect Reversed by Rescue of Amygdala PPARγ Function [J]. J Neurosci，2016，36（50）：12611-12623.
[25] 陆浩慧.小胶质细胞极化与负性情绪的相关研究[J].医学研究生学报，2017，30（8）：873-877.
[26] Zhao Q，Wang Q，Wang J，et al. Maternal immune activation-induced PPARγ-dependent dysfunction of microglia associated with neurogenic impairment and aberrant postnatal behaviors in offspring [J]. Neurobiol Dis，2019， 125：1-13.
[27] Zhao Z，Zhang L，Guo XD，et al. Rosiglitazone Exerts an Anti-depressive Effect in Unpredictable Chronic Mild-Stress-Induced Depressive Mice by Maintaining Essential Neuron Autophagy and Inhibiting Excessive Astrocytic Apoptosis [J]. Front Mol Neurosci，2017，10：293.
[28] Guo M，Li C，Lei Y，et al. Role of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors [J]. Mol Psychiatry，2017， 22（7）：1056-1068.
[29] 周屹峰，刘平，平丽英，等.GLP-1R激动剂在治疗2型糖尿病中的研究进展[J].海峡药学，2019，31（8）：1-4.
[30] Anderberg RH，Richard JE，Hansson C，et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality [J]. Psychoneuroendocrinology，2016，65：54-66.
[31] Weina H，Yuhu N，Christian H，et al. Liraglutide attenuates the depressive-and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity [J]. Brain Res，2018，1694：55-62.
[32] Gamble JM，Chibrikov E，Midodzi WK，et al. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes：a cohort study using the UK Clinical Practice Research Datalink [J]. BMJ Open，2018，8（10）：e023830.
[33] de Souza AG，Chaves Filho AJM，Souza Oliveira JV，et al. Prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide：Involvement of brain antioxidant and BDNF upregulating properties [J]. Biomed Pharmacother，2019，109：429-439.
[34] Krass M，Volke A，Rünkorg K，et al. GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment [J]. Acta Neuropsychiatr，2015，27（1）：25-32.
[35] 汤云昭，田琳琳，倪长霖.DPP-4抑制剂的安全性研究进展[J].医学综述，2018，24（4）：770-775.
[36] Sharma AN，Pise A，Sharma JN，et al. Dipeptidyl-peptidase Ⅳ（DPP-Ⅳ）inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats [J]. Metab Brain Dis，2015，30（3）：659-667.
[37] Kamble M，Gupta R，Rehan HS，et al. Neurobehavioral effects of liraglutide and sitagliptin in experimental models [J]. Eur J Pharmacol，2016，774：64-70.
[38] 王巍巍，高乐，杨俊，等.DPP-4抑制剂治疗的2型糖尿病患者中焦虑和抑郁发生风险的Network meta分析[J].中国医刊，2018，53（9）：1044-1049.
[39] Gupta D，Kurhe Y，Radhakrishnan M. Antidepressant effects of insulin in streptozotocin induced diabetic mice：Modulation of brain serotonin system [J]. Physiol Behav，2014，129：73-78.
[40] Gupta D，Radhakrishnan M，Kurhe Y. Insulin reverses anxiety-like behavior evoked by streptozotocin-induced diabetes in mice [J]. Metab Brain Dis，2014，29（3）：737-746. |
|
|
|
